Xcyte Therapies Report issue

For profit Phase 2
Founded: Seattle WA United States (1996)
Status: Acquired by Cyclacel Pharmaceuticals, Inc. (2005)

Organization Overview

First Clinical Trial
2003
NCT00078065
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2004

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

xcellerated t cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1